Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients (Q36507849)

14 August 2017

1 reference

title

Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients (English)

1 reference

14 August 2017

0 references

Brandy Panunti

1

1 reference

PubMed ID

16777491

14 August 2017

Vivian Fonseca

series ordinal

2

1 reference

14 August 2017

14 June 2006

1 reference

14 August 2017

Vascular Pharmacology

1 reference

14 August 2017

45

1 reference

14 August 2017

1

1 reference

14 August 2017

29-35

1 reference

Troglitazone and vascular reactivity: role of glucose and calcium

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Elevated Levels of Interleukin 6 Are Reduced in Serum and Subcutaneous Adipose Tissue of Obese Women after Weight Loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

7 January 2021

Adiposity and diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Adiponectin: more than just another fat cell hormone?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Relationship between plasma leptin levels and the tumor necrosis factor-alpha system in obese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Obesity and Heart Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

PPARs and the complex journey to obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Nontraditional risk factors for cardiovascular disease in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Low density lipoprotein particle size and risk factors of insulin resistance syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Risk factor clustering in the insulin resistance syndrome and its relationship to cardiovascular disease in postmenopausal white, black, hispanic, and Asian/Pacific Islander women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Roles of PPARs in health and disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Evidence for a potent antiinflammatory effect of rosiglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Atherosclerosis — An Inflammatory Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Adiponectin and protection against type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Interleukin-6 Regulates Human Adipose Tissue Lipid Metabolism and Leptin Productionin Vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.013

10.1016/J.VPH.2005.11.013

7 January 2021

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16777491